Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Boill Healthcare Holdings Limited
保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1246)

DECISION OF LISTING REVIEW COMMITTEE AND JUDICIAL REVIEW

This announcement is made by Boill Healthcare Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules**") of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated 25 July 2024 in relation to suspension of trading of the shares of the Company (the "**Shares**"); (ii) the announcements of the Stock Exchange dated 9 August 2024, 3 December 2024 and 13 February 2025 regarding the Company, which set out, among others, the resumption guidance for the resumption of trading in the Company's securities (the "**Resumption Guidance**"); (iii) the announcements of the Company dated 16 January 2026 and 25 January 2026 in relation to, among others, the progress in fulfilling the Resumption Guidance and continued suspension of trading; (iv) the announcement of the Company dated 25 January 2026 for the preliminary interim results of the Company for the six months ended 30 September 2024; (v) the announcement of the Company dated 25 January 2026 for the preliminary annual results of the Company for the year ended 31 March 2025; (vi) the announcement of the Company dated 25 January 2026 for the preliminary interim results of the Company for the six months ended 30 September 2025; (vii) the announcement of the Company dated 25 January 2026 in relation to, among others, the key findings of the independent forensic investigation and the internal control review; and (viii) the announcement of the Company dated 27 February 2026 in relation to the request for review of the decision of the listing committee (collectively, the "**Announcements**"). Unless otherwise specified, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

DECISION OF THE LISTING REVIEW COMMITTEE

As disclosed in the announcement of the Company dated 27 February 2026, on the even date, the Company submitted a written request to the Listing Review Committee to review the Decision pursuant to Chapter 2B of the Listing Rules.

The Board wishes to inform the shareholders and potential investors of the Company that the review hearing of the Listing Review Committee was held on 14 April 2026 regarding the Decision, and according to a letter issued by the Listing Review Committee dated 12 May 2026, the Company was notified that the Listing Review Committee decided to uphold the Decision under Rule 6.01A(1) of the Listing Rules (the "**LRC Decision**"). On 13 May 2026, the Stock Exchange further issued a letter advising the Company that the last day of listing of the Shares will be 22 May 2026 and the listing of the Shares will be cancelled with effect from 9:00 a.m. on 26 May 2026.

JUDICIAL REVIEW

The Company is deeply disappointed by the LRC Decision and has decided to file an application to obtain leave (the "**Leave Application**") from the High Court of Hong Kong (the "**High Court**") to apply for judicial review against the LRC Decision (the "**Judicial Review Proceedings**"). Given that the delisting is permanent and will have serious and irreversible consequences for the Company, the Company has issued a letter on 19 May 2026 to the Listing Committee, Listing Review Committee and the Listing Division of the Stock Exchange requesting the Stock Exchange to withhold its enforcement of the Decision in any manner pending the determination of the Judicial Review Proceedings, to enable adequate time for the Company for the Leave Application contemplated above to be taken out and for the High Court to consider it.

In the reply letter dated 20 May 2026, the Stock Exchange indicated that the Stock Exchange is only prepared to voluntarily refrain from implementing the Decision if the Company can identify potentially viable grounds for judicial review and the Stock Exchange is prepared to grant the Company until 4 June 2026 to proceed with the Leave Application. The Stock Exchange also indicated that should the Stock Exchange decide to proceed with implementing the Decision, the Exchange will provide the Company with not less than 7 days' notice in advance of the publication of the relevant announcement.

Further announcement(s) will be made by the Company regarding any material development of the proposed Judicial Review Proceedings and the implementation of the Decision as and when appropriate and in accordance with the Listing Rules.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange was suspended at the request of the Company with effect from 9:31 a.m. on 25 July 2024. The trading in the Shares will remain suspended until the Stock Exchange is satisfied that the Company fulfills all the Resumption Guidance.

Shareholders and potential investors of the Company should note that the intended application to judicial review does not mean the Company will not be delisted. The High Court may or may not grant leave for the judicial review and even if leave is granted, the judicial review may or may not succeed. Shareholders and potential investors of the Company who have any queries about the implications of the cancellation of listing of the Shares are advised to obtain appropriate professional advice.

By order of the Board
Boill Healthcare Holdings Limited
Zhuo Wenjie
Executive Director and Chairman

Hong Kong, 21 May 2026

As at the date of this announcement and after the above appointments and resignations, the Company has (i) three executive Directors, namely Mr. Zhuo Wenjie, Mr. Yu Sicheng and Mr. Chen Wei; (ii) one non-executive Director, namely Dr. Tang Sing Hing, Kenny; and (iii) three independent non-executive Directors, namely Mr. Yau Yan Yuen, Ms. Xiao Lihong and Mr. Liang Yanan.